Clovis Sets Brisk Development Timetable For Lung Cancer Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The oncology drug developer expects to file its third generation EGFR inhibitor for the treatment of NSCLC by the end of 2015, CEO Patrick Mahaffy told investors during an R&D day Jan. 27. Investors are enthusiastic about the potential of the drug, which could address a sizeable commercial market.